Literature DB >> 25316521

In reply.

Michael Mehring, Antonius Schneider, Johannes Fexer, Ewan Donnachie, Manfred Keller, Frank Hofmann, Stefan Wagenpfeil.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25316521      PMCID： PMC4199251          DOI： 10.3238/arztebl.2014.0646b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  3 in total

1.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

Authors:  Andrea Rossi; Peter Kristufek; Bernard E Levine; Moira H Thomson; Denise Till; John Kottakis; Giovanni Della Cioppa
Journal:  Chest       Date:  2002-04       Impact factor: 9.410

2.  Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease.

Authors:  Marie-Christyne Cyr; Marie-France Beauchesne; Catherine Lemière; Lucie Blais
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

3.  The effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program.

Authors:  Johannes Fexer; Ewan Donnachie; Antonius Schneider; Stefan Wagenpfeil; Manfred Keller; Frank Hofmann; Michael Mehring
Journal:  Dtsch Arztebl Int       Date:  2014-04-25       Impact factor: 5.594
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.